Horizon Therapeutics Plc (HZNP)

28.61
0.41 1.50
NASDAQ : Health Technology
Prev Close 28.20
Open 28.13
Day Low/High 27.87 / 28.76
52 Wk Low/High 16.56 / 29.44
Volume 1.54M
Avg Volume 1.33M
Exchange NASDAQ
Shares Outstanding 186.45M
Market Cap 5.09B
EPS -0.50
P/E Ratio 69.95
Div & Yield N.A. (N.A)
Noteworthy Thursday Option Activity: HZNP, AIRM, CVT

Noteworthy Thursday Option Activity: HZNP, AIRM, CVT

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Horizon Pharma plc , where a total volume of 22,226 contracts has been traded thus far today, a contract volume which is representative of approximately 2.2 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 80.8% of HZNP's average daily trading volume over the past month, of 2.8 million shares.

Drug Win for Depomed Could Be Hurdle for Starboard

Drug Win for Depomed Could Be Hurdle for Starboard

Increased chance for company's sale presents activist campaign with a steeper climb.

Horizon Pharma Plc Provides Update On PBM Formulary Status For Primary Care Medicines

Horizon Pharma Plc Provides Update On PBM Formulary Status For Primary Care Medicines

Secures Formulary Status with Prime Therapeutics for Primary Care Medicines

Biotech ETFs May Be a Prescription for Investment Success, Especially if Trump Becomes President

Biotech ETFs May Be a Prescription for Investment Success, Especially if Trump Becomes President

Driving sector performance are a recent series of mergers and acquisitions, including Horizon Pharma's purchase of Raptor Pharmaceutical Corp. Then there's the political boost...

Arbor and Purdue Seen as Likely Bidders for DepoMed

Arbor and Purdue Seen as Likely Bidders for DepoMed

The pharmaceutical company is reportedly up for sale after being dogged by Starboard Value for months, and could go for up to $41 million.

More Rare Disease Dealmaking to Follow Horizon's Raptor Deal

More Rare Disease Dealmaking to Follow Horizon's Raptor Deal

The buyer's CEO said it will look at both large acquisitions and Phase 2 and pre-approved assets in the wake of the $800 million purchase of the maker of Procysbi.

Horizon Pharma (HZNP) Stock Price Target Increased at Brean Capital

Horizon Pharma (HZNP) Stock Price Target Increased at Brean Capital

Horizon Pharma's (HZNP) stock price target was lifted at Brean Capital on Tuesday after the company agreed to buy Raptor Pharmaceuticals (RPTP).

Fed Dove Brainard Pushes Stocks Into Rally Mode

Fed Dove Brainard Pushes Stocks Into Rally Mode

Relief floods Wall Street on Monday after a number of Federal Reserve speakers take a dovish turn following increasingly hawkish rhetoric coming out of the central bank.

Closing Bell: Fed's Brainard Cautions 'Prudence'; U.S. Stocks Soar

Closing Bell: Fed's Brainard Cautions 'Prudence'; U.S. Stocks Soar

Relief flooded Wall Street after a number of Fed speakers took a dovish turn following increasingly hawkish rhetoric.

7 Stocks Trading on Big Volume -- and What to Do With Them Now

7 Stocks Trading on Big Volume -- and What to Do With Them Now

Here's a technical look at how to trade some of the most active stocks on the market right now.

Stocks Extend Gains as Fed's Brainard Urges 'Prudence' With Rates; Oil Gains

Stocks Extend Gains as Fed's Brainard Urges 'Prudence' With Rates; Oil Gains

Stocks rise Monday after Federal Reserve Gov. Lael Brainard urges 'prudence' in raising rates.

Stocks Rise but Come Off Highs Amid Rate Hike Worries

Stocks Rise but Come Off Highs Amid Rate Hike Worries

Stocks pare gains on Monday as worries over how soon the Federal Reserve might hike interest rates keeps markets wary.

Stock Futures Pare Losses After Fed's Lockhart Stays Coy on Interest Rates

Stock Futures Pare Losses After Fed's Lockhart Stays Coy on Interest Rates

Stock futures moved sharply lower on Monday morning, extending Friday's selloff, as worries continued over how soon the Federal Reserve might hike interest rates.

Horizon Pharma Swoops In on Raptor With $800 Million Bid

Horizon Pharma Swoops In on Raptor With $800 Million Bid

Horizon says the $800 million offer will bolster its rare disease business and its operations outside the U.S..

Horizon Pharma (HZNP) Stock Stumbles, Could Be at Risk from Clinton Drug Plan

Horizon Pharma (HZNP) Stock Stumbles, Could Be at Risk from Clinton Drug Plan

Citi said in a note Friday that Horizon Pharma (HZNP) could be hurt by Democratic presidential candidate Hillary Clinton's new drug plan.

'Mad Money' Lightning Round: I Can't Recommend Gilead

'Mad Money' Lightning Round: I Can't Recommend Gilead

Cramer says CyberArk Software is doing well but he's avoiding Clovis Oncology.

Jim Cramer's 'Mad Money' Recap: Markets Make This Economy, Not the Fed

Jim Cramer's 'Mad Money' Recap: Markets Make This Economy, Not the Fed

Cramer says he doesn't understand the obsession some investors have with the Federal Reserve. Forget the Fed.

Horizon Pharma (HZNP) Stock Pops on Q2 Beat

Horizon Pharma (HZNP) Stock Pops on Q2 Beat

Before Monday's opening bell, Horizon Pharma (HZNP) reported earnings that topped analysts' expectations for the 2016 second quarter.

TheStreet Quant Rating: C+ (Hold)